Su, Shu-Chih
Merck & Co., Inc., Rahway, NJ, USA (United States)
2 papers on CoChat
Most cited papers
- Verified
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 1,159
- Verified
Short telomeres are a risk factor for idiopathic pulmonary fibrosis
Alder, J. K., Chen, J. J.-L., Lancaster, L., Danoff, S., Su, S.-C., Cogan, J. D., Vulto, I., Xie, M., Qi, X., Tuder, R. M., et al. (2008) · Proceedings of the National Academy of Sciences
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTelomeres, Telomerase, and Senescence
Cited by 805
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free